the prevention of mother to child transmission of hepatitis B
Conditions
Interventions
Telbivudine group:oral administration
Tenofovir group :oral administration
Control group:No
Sponsors
Beijing Youan Hospital, CMU
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. CHB Pregnant woman HBsAg Postive =6 mouth HBV DNA=10E+6IU/ml; 2 Aged 18-45 years old; 3. Pregnancy women have all relevant documentation filing before12 weeks including HBsAg, HBsAb, HBeAg, HBeAb, HBcAb of hepatitis B, HBV-DNA, Genetype, HBV-DNA sequence, liver function, blood routine, liver B ultrasound et al; 4. The voluntary pregnancy received follow-up treatment antiviral nucleoside analogues and signed informed consent; 5. Pregnancy women agree to building obstetric filing pregnant childbirth in our hospital, and to follow-up according to the research project requirements in postpartum maternal; 6. According to the requirements of informed consent, Pregnancy women are able to make the corresponding testing, follow-up and intervention measures and have a good compliance.
Exclusion criteria
Exclusion criteria: 1. Combined infection with HCV, HIV, HDV, HEV, Treponema pallidum; 2. Diagnosis or suspected hepatocellular carcinoma or other malignant tumor; 3. Long term use of hormones or immunosuppressive agents; 4. Alcohol or drug addict; 5. Allergic history of nucleoside analogues; 6. Prenatal diagnosis of fetal congenital malformation; 7. Pregnant women with severe diseases of other organs affect follow-up compliance; 8. Those who need to take drugs after pregnancy or childbirth combined other disease; 9. Those who need to the long-term use of nucleoside analogues and the emergence of drug resistant before pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serology index;Virological index;Biochemistry index;hormone; | — |
Countries
China
Contacts
Public ContactZhang Hua
Beijing Youan Hospital, CMU
Outcome results
None listed